Cat. No.: HY-N0103A

Sophocarpine monohydrate

12 Cited Publications

Customer Review

Based on 12 publication(s) in Google Scholar

Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage.

For research use only. We do not sell to patients.

Purity: 99.91%
CAS No.: 145572-44-7
Formula: C₁₅H₂₄N₂O₂
Molecular Weight:264.36

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Sophocarpine monohydrate Chemical Structure

CAS No.: 145572-44-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

PI3K

All NF-κB Isoforms :

All PI3K Isoforms :

All Akt Isoforms :

All MEK Isoforms :

All ERK Isoforms :

In Vitro

Sophocarpine monohydrate (0.5-4 mM; 24-48 h) inhibits cell viability, proliferation and migration, induces cell cycle G0/G1 arrest and apoptosis, upregulates PTEN and downregulates PI3K/Akt signaling pathways in glioblastoma cells (U251, C6)^[1].
Sophocarpine monohydrate (0.4 mM; 24-72 h) inhibits cell proliferation and migration, downregulates MEK/ERK phosphorylation and VEGF-A/C/D secretion, and reduces N-cadherin and MMP-9 expression in colorectal cancer cells (HCT116, SW620)^[2].
Sophocarpine monohydrate (50-100 μg/mL; 24 h) inhibits LPS-induced NO, TNF-α, and IL-6 production in RAW 264.7 macrophages, downregulates iNOS and COX-2 protein expression, and inhibits NF-κB activation and p38 and JNK phosphorylation in RAW 264.7 macrophages^[3].
Sophocarpine monohydrate (1-5 μM; 24 h pretreatment + 12 h DOX cotreatment) reduces ROS levels in H9C2 cardiomyocytes, upregulates Nrf2/HO-1 signaling, inhibits DOX (HY-15142A)-induced Bax and cleaved-caspase-3 expression, and upregulates Bcl-2 in H9C2 cardiomyocytes^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

U251, C6 glioblastoma cells
Concentration:

0.5, 1, 2, 4 mM
Incubation Time:

24-48 h
Result:

Reduced cell viability in a dose- and time-dependent manner, with IC₅₀ around 2 mM at 48 hours, as measured by CCK-8 assay.
No significant cytotoxicity was observed in primary astrocytes at these concentrations.

Apoptosis Analysis^[1]

Cell Line:

U251 glioblastoma cells
Concentration:

2 mM
Incubation Time:

24 h
Result:

Resulted a significant increase in subG1 phase cells (apoptotic cells) and G0/G1 phase arrest.

Western Blot Analysis^[1]^[2]

Cell Line:

U251 glioblastoma cells^[1] HCT116, SW620 colorectal cancer cells^[2]
Concentration:

2 mM for U251 cells; 0.4 mM for HCT116, SW620 cells
Incubation Time:

24 h, 48 h
Result:

Upregulation of cleaved Caspase-3, P53, and downregulation of Bcl-2, indicating induction of intrinsic apoptosis in U251 cells^[1].
Downregulated phosphorylated MEK (p-MEK), phosphorylated ERK (p-ERK), N-cadherin, and MMP-9 in HCT116, SW620 cells, while VEGF-A/C/D secretion reduced^[2].

In Vivo

Sophocarpine (35 mg/kg; intraperitoneal injection; once every 2 days; 2 weeks) monohydrate inhibits tumor growth, upregulates PTEN expression, downregulates Akt phosphorylation, and induces tumor cell apoptosis in BALB/c nude mouse subcutaneous and orthotopic glioma transplantation models^[1].
Sophocarpine (10-30 mg/kg; intraperitoneal injection; twice a week; 4 weeks) monohydrate improves cardiac function, reduces CK, CK-MB, and LDH levels, and alleviates oxidative stress and cardiomyocyte apoptosis in a DOX (HY-15142A)-induced cardiac injury model in C57BL/6J mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c Nude Mouse Glioblastoma Xenograft Model (male, 18-24 g, 6-8 weeks old): subcutaneous and orthotopic U251 glioblastoma xenografts^[1]
Dosage:

35 mg/kg Sophocarpine
Administration:

Intraperitoneal injection, every 2 days for 2 weeks (subcutaneous model); daily for 2 weeks (orthotopic model)
Result:

Significantly reduced subcutaneous tumor volume and weight by 50% compared to control.
Echocardiography and histology showed no cardiotoxicity.
Western blot in tumor tissues revealed upregulated PTEN and cleaved Caspase-3, downregulated p-Akt and Bcl-2, indicating activation of the PTEN/PI3K/Akt pathway to induce apoptosis.
Immunohistochemistry confirmed reduced Ki-67 proliferation marker and increased PTEN expression.

Animal Model:

C57BL/6J Mouse Doxorubicin-Induced Heart Injury Model (male, 25 g, 7 weeks old): Doxorubicin (5 mg/kg weekly×4 weeks) induced cardiotoxicity^[4]
Dosage:

10 mg/kg or 30 mg/kg Sophocarpine
Administration:

Intraperitoneal injection, co-administered with Doxorubicin weekly for the last 2 weeks (after initial 2 weeks of doxorubicin alone), total 4 weeks
Result:

Echocardiography showed improved left ventricular ejection fraction (LVEF) and fractional shortening (LVFS).
Serum biomarkers CK, CK-MB, and LDH were reduced by 30-40% compared to doxorubicin group.
DHE staining revealed decreased myocardial superoxide production, while MDA levels were lowered and SOD/GSH increased.
Western blot showed upregulated Nrf2/HO-1 signaling, reduced NOX-4 and pro-apoptotic proteins (Bax, cleaved-caspase-3, Cyto-C), and increased anti-apoptotic Bcl-2 in heart tissues.

Chemical Information

CAS No. 145572-44-7
Appearance Solid
Molecular Weight 264.36
Formula C₁₅H₂₄N₂O₂
Color Light yellow to yellow
SMILES

O=C1N(C[C@@]2([H])[C@@]3([H])[C@]4([H])CCCN3CCC2)[C@]4([H])CC=C1.O
Structure Classification
- Alkaloids
- Piperidine Alkaloids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (12)

All WBIF

Sort by:

Journal Impact Factor

Phytomedicine

Sophocarpine suppresses MAPK-mediated inflammation by restoring gut microbiota in colorectal cancer. [Abstract]

2025 May 6:143:156833. PMID: 40393246
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Acta Pharmacol Sin

Sophocarpine alleviates chronic itch in mouse atopic dermatitis by inhibiting spinal astrocyte reactivity and pro-inflammatory signaling. [Abstract]

2026 Jan 7. PMID: 41501419
J Ethnopharmacol

Isoxanthohumol, a component of Sophora flavescens, promotes the activation of the NLRP3 inflammasome and induces idiosyncratic hepatotoxicity. [Abstract]

2022 Mar 1:285:114796. PMID: 34740771
Eur J Pharmacol

The protective effects of sophocarpine on sepsis-induced cardiomyopathy. [Abstract]

2023 Jul 5:950:175745. PMID: 37146706

Sophocarpine monohydrate purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Jul 5:950:175745. [Abstract]

Sophocarpine (20 mg/kg; i.p.; daily; one week) significantly reduces the level of oxidative stress in mice.

Sophocarpine monohydrate purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Jul 5:950:175745. [Abstract]

Sophocarpine (20 mg/kg; i.p.; daily; one week) and LPS together significantly increases the expression of Nrf2 and HO-1 in mice.
Int Immunopharmacol

Minimolide F alleviates inflammatory diseases by specifically targeting STING and blocking IRF3 recruitment. [Abstract]

2026 May 1:176:116468. PMID: 41819671
Molecules

Sophocarpine Alleviates Isoproterenol-Induced Kidney Injury by Suppressing Inflammation, Apoptosis, Oxidative Stress and Fibrosis. [Abstract]

2022 Nov 15;27(22):7868. PMID: 36431969

Sophocarpine monohydrate purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Nov 15;27(22):7868. [Abstract]

Sophocarpine (SOP; 20, 40 mg/kg; i.p.; once per day over two weeks) significantly hinders the ISO(Isoproterenol)-induced increase in TLR-4 and phosphorylation of NF-κB in mice.
Mediators Inflamm

Targeting Pulmonary Hypertension: Elucidating Sophocarpine's Protective Role via Preclinical Models. [Abstract]

2026 Feb 23:2026:5524066. PMID: 41737847
Sci Rep

Sophocarpine alleviates doxorubicin-induced heart injury by suppressing oxidative stress and apoptosis. [Abstract]

2024 Jan 3;14(1):428. PMID: 38172265
FASEB J

LAPTM5 Promotes Age-Related Renal Fibrosis via USP10/PTEN-Mediated Autophagy Inhibition. [Abstract]

2026 May 31;40(10):e71905. PMID: 42149696
PeerJ

Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer. [Abstract]

2022 Sep 16;10:e14042. PMID: 36132221
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (378.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7827 mL

18.9136 mL

37.8272 mL

5 mM

0.7565 mL

3.7827 mL

7.5654 mL

10 mM

0.3783 mL

1.8914 mL

3.7827 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Xing S, et al. Sophocarpine inhibits the progression of glioblastoma via PTEN/PI3K/Akt signaling pathway. Am J Cancer Res. 2024 Aug 25;14(8):3757-3772. [Content Brief]

[2]. Wang Q, et al. Sophocarpine Inhibits Tumorgenesis of Colorectal Cancer via Downregulation of MEK/ERK/VEGF Pathway. Biol Pharm Bull. 2019 Nov 1;42(11):1830-1838. [Content Brief]

[3]. Gao Y, et al. Anti-inflammatory effects of sophocarpine in LPS-induced RAW 264.7 cells via NF-κB and MAPKs signaling pathways. Toxicol In Vitro. 2012 Feb;26(1):1-6. [Content Brief]

[4]. Zhang HJ, et al. Sophocarpine alleviates doxorubicin-induced heart injury by suppressing oxidative stress and apoptosis. Sci Rep. 2024 Jan 3;14(1):428. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7827 mL	18.9136 mL	37.8272 mL	94.5680 mL
	5 mM	0.7565 mL	3.7827 mL	7.5654 mL	18.9136 mL
	10 mM	0.3783 mL	1.8914 mL	3.7827 mL	9.4568 mL
	15 mM	0.2522 mL	1.2609 mL	2.5218 mL	6.3045 mL
	20 mM	0.1891 mL	0.9457 mL	1.8914 mL	4.7284 mL
	25 mM	0.1513 mL	0.7565 mL	1.5131 mL	3.7827 mL
	30 mM	0.1261 mL	0.6305 mL	1.2609 mL	3.1523 mL
	40 mM	0.0946 mL	0.4728 mL	0.9457 mL	2.3642 mL
	50 mM	0.0757 mL	0.3783 mL	0.7565 mL	1.8914 mL
	60 mM	0.0630 mL	0.3152 mL	0.6305 mL	1.5761 mL
	80 mM	0.0473 mL	0.2364 mL	0.4728 mL	1.1821 mL
	100 mM	0.0378 mL	0.1891 mL	0.3783 mL	0.9457 mL

Keywords

Sophocarpine monohydrate

12 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Sophocarpine monohydrate

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library